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Cdx2 is a homeobox domain-containing transcription factor that is important in the development and
differentiation of the intestinal cells, and served as a potential biomarker of tumor progression in early
intestinal-type gastric cancer. However, its prognostic value and significance in gastric cancer remain controversial.
A meta-analysis based on published studies was performed to obtain an accurate evaluation of the association
between the presence of Cdx2-positive in clinical samples and clinical outcome. A total of 13 eligible retrospective
cohort studies with 1513 patients were included. Cdx2-positive cases were significantly associated with higher
male-to-female ratio (RR=1.27, 95% CI: 1.17–1.38, P<0.00001 fixed-effect), lower (I+II) clinical stage (RR=1.63,
95% CI: 1.42–1.87, P<0.00001 fixed-effect), better histologic differentiation (RR=1.54, 95% CI: 1.34-1.76, P<0.00001
fixed-effect), and lower rate of vascular invasion (RR=1.23, 95% CI: 1.08-1.41, P=0.002 fixed-effect) and lymph node
metastasis (RR=1.52, 95% CI: 1.33-1.73, P<0.00001 fixed-effect), as well as higher 5-year survival rate (HR=2.22,
95% CI: 1.78-2.75, P<0.00001 fixed-effect). However, the presence of Cdx2 was not associated with tumor size. In
summary, Cdx2 is a prognostic factor in gastric cancer, which acts as a marker of good outcome in patients with
gastric cancer. Further clinical studies are needed to confirm the role of Cdx2 in clinical practice.
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Despite the decline in its incidence in the past few de-
cades, gastric cancer remains the second and fourth
leading cause of cancer-related death in men and women
respectively [1]. Patients with gastric cancer have excel-
lent survival if there is no regional lymph node involve-
ment [2]. Unfortunately, gastric cancer is difficult to be
diagnosed at an early stage. As a result, there is great
interest in finding a prognostic marker for this poten-
tially curable group of patients.
The transcription factor Cdx2 is a member of the
caudal-related homeobox gene family, which plays an
important role in the proliferation and differentiation of
intestinal epithelial cells, and is involved in the* Correspondence: xiaoqiang20050@yahoo.com.cn; xieyubo715001@yahoo.
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reproduction in any medium, provided the ordevelopment and progression of gastric cancer [3,4]. A
number of reports suggest that Cdx2 expression is a
characteristic feature of human gastric cancer and
served as a potential biomarker of tumor progression in
early gastric carcinoma [5-8]. However, the relation be-
tween Cdx2 expression and clinicopathological features
remains controversial. So far several studies have
demonstrated that Cdx2-positive expression in gastric
cancer was significantly correlated with better differen-
tiation and lower rate of lymph node metastasis [9-11].
However, Xiao and colleagues showed that there was not
association between Cdx2 expression and lymph node
metastasis of gastric carcinoma [12]. The limited avail-
ability of samples might result in variations in the cli-
nical significance of the results. Thus, this meta-analysis
was conducted to determine the association between
Cdx2 and common clinicopathological features of gastric
cancer as well as 5-year survival rate, and to consider
the significance of Cdx2 expression in the prediction of
outcome in gastric cancer.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Literature search strategy
A computerized literature search on Cochrane Library,
MEDLINE, EMBASE, CNKI (Chinese National Know-
ledge Infrastructure Database), Wangfang (Database of
Chinese Ministry of Science & Technology), and CBM
(China Biological Medicine Database) was performed
from the earliest possible date until July 30, 2012 (CNKI,
Wangfang and CBM Database are the top three Chinese
medical databases). The search terms included “gastric
cancer” OR “gastric carcinoma” OR “carcinoma of sto-
mach” OR “stomach neoplasms” AND “Cdx2” OR “cau-
dal type homeobox 2”. The search was limited in studies
in humans. Titles and abstracts of all citations were
screened independently by two reviewers (Wang XT and
Kong FB). We did not consider abstracts or unpublished
reports. If more than 1 article was published by the same
author using the same case series, we selected the study
where the most individuals were investigated.Inclusion and exclusion criteria
To be eligible for this review, trials had to deal with
gastric cancer only, to measure Cdx2 expression in the
primary tumor (not in metastatic tissue or in tissue ad-
jacent to the tumor), to evaluate correlation of Cdx2
expression and patients’ clinicopathological characteris-
tics or 5-year survival rate, and to be published as a full
paper in English or Chinese language literature.
We reviewed abstracts of all citations and retrieved
studies. For inclusion in the meta-analysis, the identified
articles have to provide information on: (a) tumors veri-
fied by pathological examination; (b) methods used to
determine Cdx2 expression and assign expression status
by immunohistochemistry (IHC); (c) no preoperative
radiotherapy and/or chemotherapy administered to the
patients; (d) evaluation of the association between Cdx2
expression and prognostic factors of gastric cancer; (e)
inclusion of sufficient data to allow the estimation of an
relative risk (RR) with a 95% confidence interval (95% CI);
(f) peer-reviewed and published original articles. Major
reasons for exclusion of studies were: (a) Cdx2 expres-
sion was not evaluated by IHC; (b) no control; (c) dupli-
cate; (d) no usable data reported; (e) cells or animals
experiment; (f) letters to the editor, reviews, and articles
published in a book.Data acquisition and quality assessment
Samples were classified as positive if at least 5% of the
tumor cells were stained in continuous scales or at least
moderate staining in qualitative scales. The above cutoff
was used by the majority of studies [11,13-17]. When
different definitions were used we contacted the primary
investigators, and when data with this cutoff were notpossible to retrieve we accepted the cutoff that was clo-
sest to this 5% cutoff level.
In addition,there were two kinds of definition of the
Cdx2 positive-expressed patients in IHC. The first of
them was defining staining of nuclear or cytoplasmic or
both as positive, which was used by most of the investi-
gators. The second method was defining nuclear and
cytoplasmic staining as positive separately in IHC exam-
ination, which was used only in 3 studies. We made an
effort to contact all primary authors of studies by e-mail
to standardize their data according to the meta-analysis
definitions whenever possible. In the present study, only
nuclear staining was regarded as positive [18-20].
All data were extracted independently by 2 reviewers
(Wang XT and Kong FB) according to the prespecified
selection criteria. The following data were extracted: the
year of publication, first author’s surname, number of
cases and controls, and numbers of different clinical and
pathologic parameters.Statistical analysis
Results were expressed with risk ratio (RR) for dicho-
tomous data, and 95% confidence intervals (CI) were
counted [21]. P<0.05 was required for the overall RR to
be statistically significant. The between-study heteroge-
neity was assessed using I2 and χ2 measures. The pooled
statistical analysis was calculated using the fixed effects
model, but a random-effect model was performed when
the P value of heterogeneity test was <0.1. The data on
the predictive ability of Cdx2 overexpression for 5-year
survival rate were combined across studies using fixed
and random effect models for the synthesis of hazard
ratio (HR). The HR of 5-year survival rate was calculated
from the reported data directly by number of events
within 5 years after surgery was used, or data reading
from Kaplan-Meier survival curve. The funnel plot
was examined to explore the possibility of publication
bias [21-23].
Kaplan-Meier curves were read by Engauge Digitizer
version 2.11 (free software downloaded from http://source-
forge.net). The data analysis was performed using the
meta-analysis software Review Manager (RevMan) v5.0.17
(Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2008; http://cc-ims.net/revman/download).Results
Eligible studies
As shown in Figure 1, our initial search yielded 412
studies. According to the inclusion and exclusion cri-
teria, 13 papers [9,11,13-16,24-30] were recruited into
our meta-analysis. Only four studies reported the asso-
ciation between the Cdx2 and 5-year survival rate
[9,15,16,26]. Studies were carried out in Japan, China,
Figure 1 Flow chart for our meta-analysis.
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characteristics for the included trials.
Correlation of Cdx2 with clinicopathological parameters
The putative Cdx2 were not associated with tumor size
(pooled RR=0.95, 95% CI: 0.73-1.24, P=0.71 random-
effect) (Figure 2B). However, Cdx2 expression in gastric
cancer was associated with biologically aggressive phe-
notypes such as sex (pooled RR=1.27, 95% CI: 1.17–1.38,
P<0.00001 fixed-effect), clinical stage (pooled RR=1.63,
95% CI: 1.42–1.87, P<0.00001 fixed-effect), tumor differ-
entiation (pooled RR=1.54, 95% CI: 1.34-1.76, P<0.00001
fixed-effect), vascular invasion (pooled RR=1.23, 95% CI:
1.08-1.41, P=0.002 fixed-effect) and lymph node metas-
tasis (pooled RR=1.52, 95% CI: 1.33-1.73, P<0.00001
fixed-effect). In other word, the incidence of Cdx2-
positive expression was significantly higher in males than
in females, significantly higher in the well and mode-
rately type gastric cancer than poorly differentiated type,
and significantly lower in carcinomas in stages III+IV
than in stage I+II (Figure 2A, 2C-D). Increased Cdx2expression was correlated with a lower proportion of vas-
cular invasion and lymph node metastasis (Figure 2E-F).
Impact of Cdx2 on 5-year survival rate of patients with
gastric cancer
The different data acquired from previous studies on the
impact of Cdx2 on 5-year survival rate enabled a quanti-
tative aggregation of the survival results. The pooled HR
of four studies containing 475 patients was analyzed
using the methods described above. The presence of
Cdx2-positive was significantly associated with higher
5-year survival rate. The pooled HR of the overall effect
was 2.22 (95% CI: 1.78-2.75, P<0.00001) in the fixed
effects model (Figure 3).
Publication bias
Publication bias was assessed using the inverted funnel
plot approach recommended for meta-analyses [31]. We
conducted funnel plots for all comparisons, and
inspected its asymmetry visually. The shapes of the fun-
nel plots showed that a low potential for publication bias
Table 1 Study characteristics for the included studies
Autor
(year-country)
Total number of patients Median
age
(range)














Ge [34] 59 107 52.2 37:22 51:56 Yes Yes
(2008-china) (32–72)
Okayama [14] 55 80 63.4 46:9 45:35 Yes Yes
(2009-Japan) (31–87)
Kim [5] 150 109 57.8 114:36 61:48 Yes Yes
(2006- Korea)
Roessler [15] 109 81 61.1 57:52 33:48 Yes Yes
(2005-Germany)
Fan [16] 40 69 59 33:7 42:27 Yes Yes
(2005-china) (29–82)
Bai [17] 36 55 62.78 28:8 43:12 Yes Yes
(2007-china) (19–87)
Zhang [27] 57 52 62.43 Unclear Unclear Yes Yes
(2009-Japan)
Zhou [28] 49 81 52 40:9 49:32 Yes Unclear
(2006-china) (34–73)
Hu [29] 27 25 57 Unclear Unclear Yes Unclear
(2009-china) (35–78)
Liu [30] 25 25 53.2 20:5 18:7 Yes Yes
(2007-China) (38–74)
Oz [26] 37 33 64.62 Unclear Unclear Yes Yes
(2011-Turkey) (26–80)
Qin [12] 41 44 61.75 30:11 30:14 Yes Yes
(2012-China) (20–87)
Chu [31] 30 37 61 23:7 26:11 Yes Yes
(2011-china) (35–87)
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evaluate the influence of single study on the summary
effect. The meta-analysis was not dominated by any indi-
vidual study, and removing any study at a time made no
difference.
Discussion
Gastric cancer is a markedly heterogeneous disease in
histologic feature and biological characters, especially in
the advanced stages [32]. A number of clinical studies
revealing its biological behavior and prognosis could be
significantly different among patients at the same stages
and with the same histological types or differentiation
grades [33-35]. Thus, it is important to find a biomarker
to indicate the biological characters and predict the out-
come of patients with gastric carcinoma.
Since their original identification in Drosophila, the
caudal related homologues (Cdx1 and Cdx2) have beenknown to be involved in the regulation of proliferation
and differentiation of intestinal epithelial cells [36]. Cdx2
was bound to the Cdx1 promoter region in the intestinal
metaplasia and the normal intestine, and upregulated the
transcriptional activity of the Cdx1 gene in the human
gastric carcinoma [37]. Thus, Cdx2, as a member of this
gene family, is crucial for Cdx-dependent program. In
adults, the structural and functional overexpression of
Cdx2 in tumors, compared with normal mucosa, suggests
that Cdx2 could play a pivotal role in the development of
intestinal metaplasia [17]. The implication of Cdx2 in in-
testinal metaplasia has been demonstrated in the intestinal
metaplasia of the stomach where Cdx2 was ectopically
overexpressed, suggesting that it could play a major role
during intestinal metaplasia formation in the stomach
[17]. Intestinal metaplasia has been shown to be a precur-
sor of intestinal-type gastric adenocarcinoma. Long-term
intestinal metaplasia induced gastric adenocarcinoma in
Figure 2 Forest plot of RR was assessed for association between Cdx2 and clinical pathologic features, such as sex (A), tumor size (B),
clinical stage (C), differentiation (D), vascular invasion (E), and lymph node metastasis (F).
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Figure 3 Forest plot of HR for 5-year survival rate among included studies. It shows the combined HR which is calculated by a fixed-effects
mode, and it demonstrates that Cdx2 can work as prognostic factors on 5-year survival rate in gastric cancer patients.
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changes were noted in wild-type littermate [38]. The
tumor incidence was 100% at 100 weeks after birth [39]. It
can be concluded that Cdx2 expression was a precursor of
gastric carcinoma and served as a reliable tumor marker
in gastric cancer.
Whether Cdx2-positive expression could be consi-
dered as a prognostic factor for gastric cancer patients is
still in dispute at the present time. Several investigators
reported that Cdx2 reduced cell proliferation rates, and
Cdx2-positive expression was decreased progressively
with the depth of tumor invasion and advancing stage
of gastric cancer [9,14,40]. They indicated that Cdx2
was an independent prognostic indicator for gastric
carcinoma. However, other studies showed that no sig-
nificant correlation could be determined between Cdx2
and clinicopathological parameters such as tumoe size,
invasion and metastasis of lymph node in gastric cancer
[12,15,24]. These researches suggested that Cdx2 did
not affect the progression of human gastric cancer. Our
previous study also showed that both the upregulation
and downregulation of Cdx2 could suppress human gas-
tric cancer progression [4,41]. These conflicting results
were likely due to small sample size of the study. Meta-Figure 4 Funnel plot of studies of Cdx2 positivity in gastric cancer.analysis was originally developed to combine the results
of randomized controlled trails, and recently this ap-
proach has been applied successfully for identification
of prognostic indicators in patients with malignant di-
seases [42-44].
This meta-analysis is the first study to systematically
estimate Cdx2 expression and its relationship with the
patients’ clinicopathological characteristics and 5-year
survival rate. Statistical significant was reached when ei-
ther all patients were enrolled or only patients who
received radical surgery were enrolled into this analysis.
This research is potentially important for prognostic rea-
sons and treatment purposes, in addition to improve the
survival rate of gastric cancer. Identification of prognos-
tic factors allows the definition of high-risk groups of
patients for whom specific therapy might be necessary.
The presence of both significant and non-significant
studies addressing the importance of Cdx2 in gastric
cancer made it necessary to find a quantitative aggrega-
tion of the survival results. The present results indicate
that Cdx2 overexpression, as detected by immunohisto-
chemistry, were significantly associated with sex, clinical
stage, differentiation, vascular invasion and lymph node
metastasis, as well as 5-year survival rate. In the present
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with male gender. Roessler et al. showed that patients’
gender was not related to Cdx2 expression, but only a
small number of patients were enrolled in that study
[14]. There are some reports that intestinal-type cancer
is proportionately more common in men [45,46] and the
fact that Cdx2 is associated with differentiated gastric
carcinoma [47-49] may help to explain our results. We
also observed a correlation of Cdx2 positivity with lower
(I+II) clinical stage, better histologic differentiation, and
lower rate of vascular invasion and lymph node metasta-
sis. Cdx2-posititive gastric cancer patients also displayed
higher 5-year survival rate than Cdx2-negative. More-
over, although there was not a significant correlation be-
tween Cdx2 expression and tumor size, we detected a
trend for smaller tumor size (<5 cm) to be associated
with Cdx2-positive. The reason for this results may be
too samll sample size included in the meta-analysis. We
still need more patients and studies as the evidences to
confirm or to refute our findings in the future.
Interestingly, some studies have examined Cdx2 in
gastric cancer using methods other than immunohisto-
chemistry (reverse transcription-PCR, immunofluores-
cence or western blot). However, only one of these
studies had performed the correlation between Cdx2
and clinicopathological features by RT-PCR. The results
showed that Cdx2-positive expression had a significant
correlation with clinical stage and lymph node metasta-
sis (data not shown). Thus, even if results obtained with
different methods are not interchangeable, these findings
are consistent with our meta-analysis.
Certain limitations in the present meta-analysis need
to be pointed out. First of all, only published studies
were included in the meta-analysis. Therefore, publica-
tion bias may have occurred, even though the use of a
statistical test did not show it [50]. We tried to retrieve
all relevant data that was not available from the pub-
lished reports, but it is unavoidable that some data
could still be missing. Missing information may reflect
“negative” or more conservative association of Cdx2
with clinicopathological parameters or 5-year survival
rate that could reduce the significance of Cdx2 expres-
sion as a predictor of of outcome in gastric cancer.
Second, in prognostic factors meta-analyses, variability
in definitions, outcomes, measurements, and experi-
mental process may contribute to between-study hete-
rogeneity [51]. In this paper, we tried to optimize
standardization, but some remaining variability in defi-
nitions was unavoidable. Although the final estimations
of the synthesis of studies using the standardized cutoff
did not differ significantly from the overall results in
the total study population, conclusions need to be
drawn cautiously [51,52]. Third, although Cdx2 expres-
sion is associated with earlier stage of disease, it isimpossible to make a stage-adjusted analysis because
there are not sufficient datas in this meta-analysis. How-
ever, we found trends for modest correlations of Cdx2
positivity with higher 5-year survival rate in whatever
clinical stage. Even then, it might be difficult to arrive at
robust conclusions. Fourth, Age is an important risk fac-
tor for gastric cancer. Because the poorly cohesive can-
cer may be occurred in young age and symptom based
diagnosis, and differentiated cancer may be more preva-
lent in old age patients, the possible confounding or se-
lection bias by age may not be excluded. Finally, the
available data do not evaluate whether Cdx2 may in-
fluence the response to specific therapeutic regimens.
Therefore, we minimized the bias by confirming a
detailed protocol before initiating the study, by perfor-
ming a carefully search for published studies, and by
using explicit methods for study selection, data extrac-
tion, and data analysis.
In conclusion, our meta-analysis suggests that Cdx2
expression might be a good prognostic factor for survival
in patients with gastric cancer, if detected by immuno-
chemistry. However, because of the heterogeneities of
included studies and bias of meta-analysis, our conclu-
sions need to be interpreted with caution. In order to
become a useful prognostic factor at the level of indivi-
dual patient and in the context of targeted therapy, these
results need to be confirmed by an adequately designed
prospective study, and larger clinical trails with widely
accepted assessment methods are necessary to define the
precise prognostic significance for Cdx2 in gastric cancer
patients.
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